Alterity Therapeutics Limited (ATHE)
- Previous Close
4.3500 - Open
4.2200 - Bid 3.6500 x 100
- Ask --
- Day's Range
3.9400 - 4.2200 - 52 Week Range
1.0000 - 5.8700 - Volume
175,266 - Avg. Volume
45,866 - Market Cap (intraday)
63.119M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8400 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
alteritytherapeutics.comRecent News: ATHE
View More
Performance Overview: ATHE
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATHE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHE
View MoreValuation Measures
Market Cap
63.12M
Enterprise Value
60.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
12.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-78.37%
Return on Equity (ttm)
-155.77%
Revenue (ttm)
3.72M
Net Income Avi to Common (ttm)
-19.79M
Diluted EPS (ttm)
-1.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.54M
Total Debt/Equity (mrq)
1.36%
Levered Free Cash Flow (ttm)
-8.87M